- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03771183
Loreline Study: Characterization of Long Responders Under Eribuline (Loreline)
National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN®) Metastatic Breast Cancer Patients
There is currently no strict recommendations for the management of patients who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy for advanced breast cancer. However, Halaven® can represent a therapeutic alternative at this stage of the disease.
Indeed, since march 2011, Halaven® has been granted Marketing Authorization (MA) for patients with metastatic or locally advanced breast cancer, whose disease has progressed after at least two lines of chemotherapy for advanced disease (3rd line). In these patients, the indication for marketing authorization specifies that the previous treatment must have included an anthracycline and a taxane except in patients who can not receive these treatments.
An extension of indication was obtained on 27/06/2014 with a marketing authorization obtained in the treatment of locally advanced or second-line metastatic breast cancer.
According to the Transparency Commission of the High Authority of Health (HAS dated September 23, 2015), Halaven® (Eribulin), administered as monotherapy, in the third line of treatment and beyond, represents a therapeutic option, because it brings an improvement of medical service rendered compared to Capecitabine (XELODA®) and Vinorelbine (NAVELBINE®).
In addition, Halaven® (Eribuline) administrated as monotherapy in second-line of treatment is an alternative to other monotherapies recommended for the treatment of locally advanced or metastatic relapsed breast cancer, such as Capecitabine (XELODA®). and Vinorelbine (NAVELBINE®). But, no improvement of medical service rendered has been reported in second line of treatment.
According to these results, it would be interesting to have additional data concerning the use of Halaven® (Eribulin), in the second and third lines, but also in the fourth line.
For this purpose, the investigators propose to perform a study in patients with metastatic breast cancer who have failed treatment after the first line and beyond.
In this study, the investigators will be particularly interested in "long-responder" patients, that is to say, in objective response or with stability for 6 months or more under Halaven®, in order to better characterize these patients. Patients must have been treated by Halaven between September 2011 and December 2016, to have a sufficient follow-up for the survival data of the patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will perform a cross-sectional study in patients with metastatic breast cancer who have failed treatment after the first line and beyond.
In this study, the investigators will be particularly interested in "long-responder" patients, that is to say, in objective response or with stability for 6 months or more under Halaven®, in order to better characterize these patients. Patients must have been treated by Halaven between September 2011 (the year of obtaining the MA in the 3rd line of treatment) and December 2016, to have a sufficient follow-up for the survival data of the patients.
The investigators will also focus on patients with liver metastases because there is limited data in this population.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Besançon, France, 25030
- CHRU Jean Minoz
-
Clermont-Ferrand, France, 63011
- Centre Jean Perrin
-
Saint Priest en Jarez, France, 42270
- Institut de Cancerologie Lucien Neuwirth
-
Strasbourg, France, 67065
- Centre PAUL STRAUSS
-
Vandœuvre-lès-Nancy, France, 54519
- Institut de Cancérologie de Lorraine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
This is a nationale, multicentric, retrospective study in which will be inclused metastatic breast cancer patients treated by Halaven® in second, third line or fourth line.
Only "long responder" patients treated by Halaven®, since Septembre 2011 to December 2016, will be included in this study.
A patient will be considered as " long responder " if she is in objective response or stability for 6 months or more from the start of Halaven® treatment
Description
Inclusion Criteria:
- Women aged between 18 and 75 years
- Metastatic breast cancer patient
- Patients treated by Halaven® in second, third or fourth line of treatment for their metastatic breast cancer
- Halaven® treatment must have been received between September 2011 and December 2016
- Patients responding or in stability during at least 6 months under Halaven® treatment
- Patients pretreated by at least one line of any other chemotherapy
- Non opposition form dated and signed by the investigator (attesting that the patient consented orally that clinical, biological and imaging data concerning her were analyzed in this study)
Exclusion Criteria:
- Male
- Patient with cognitive and psychiatric disorders
- Patient deprived of liberty by judicial or administrative decision
- Insufficient knowledge or understanding of the French language which does not allow for the non-opposition form to be understood
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure patient's age at the beginning of Halaven® treatment in patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
-patient's age at the beginning of Halaven® treatment
|
up to at least 6 months after Halaven® start
|
Characterize tumor of patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
histological tumoral type
|
up to at least 6 months after Halaven® start
|
Characterize patients who received Halaven® and who were in response since 6 months or more, according to previous treatments (neoadjuvant and/or adjuvant treatments)
Time Frame: up to at least 6 months after Halaven® start
|
number of patients who have received neoadjuvant treatments number of patients who have received adjuvant treatments
|
up to at least 6 months after Halaven® start
|
Characterize patients who received Halaven® and who were in response since 6 months or more, according to the number of lines of treatment received for metastatic disease
Time Frame: up to at least 6 months after Halaven® start
|
-number of lines of treatment received for metastatic disease, including treatment received before Halaven®
|
up to at least 6 months after Halaven® start
|
Characterize metastatic localizations of patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
number of patients with metastatic localizations
|
up to at least 6 months after Halaven® start
|
Characterize patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
number of patients with liver metastasis, surgery of liver metastasis
|
up to at least 6 months after Halaven® start
|
Measure the number of Halaven® injections to obtaine the "best" response in patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
-number of Halaven® injections until the " best " response is obtained
|
up to at least 6 months after Halaven® start
|
Measure the best response under Halaven® in patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
-duration of the " best " response under Halaven® (in months)
|
up to at least 6 months after Halaven® start
|
Measure hormonal receptors tumours of patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
hormonal receptors of primitive tumor (percentage of stained cells)
|
up to at least 6 months after Halaven® start
|
Measure KI-67 tumours of patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
-pathology of primitive cancer : ki-67
|
up to at least 6 months after Halaven® start
|
Measure Scarff Bloom Richardson grade tumours of patients who received Halaven® and who were in response since 6 months or more
Time Frame: up to at least 6 months after Halaven® start
|
-pathology of primitive cancer : Scarff Bloom Richardson grade The Scarff Bloom Richardson garde will be measured with a scale from I to III.
A grade III represent a worse outcome.
|
up to at least 6 months after Halaven® start
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure Percentage of long responders patients under Halaven® among patients treated by Halaven® in second, third and fourth line of treatment
Time Frame: up to at least 6 months after Halaven® start
|
Percentage of patients in objective response or in stability during 6 months and more since the beginning of Halaven® treatment among all patients treated by Halaven® (in second, third and fourth line of treatment).
This percentage will be collected in each participating center at the end of the study.
|
up to at least 6 months after Halaven® start
|
-Evaluate the percentage of patients with hepatic metastases
Time Frame: up to at least 6 months after Halaven® start
|
-Percentage of liver metastatic patients
|
up to at least 6 months after Halaven® start
|
-Evaluate the specific response and/or stability in patients with hepatic metastases, that is measure percentage of liver metastatic patients in complete or partial response or in stability under Halaven®
Time Frame: up to at least 6 months after Halaven® start
|
-Percentage of liver metastatic patients in complete or partial response or in stability under Halaven®
|
up to at least 6 months after Halaven® start
|
-Evaluate toxicities due to the use of Halaven®
Time Frame: up to at least 6 months after Halaven® start
|
Number and percentage of patients who have a grade 3 and a grade 4 toxicity (for each toxicity reported) -Collection of toxicities under Halaven® Toxicities considered are toxicities grade 3, 4 and 5 (CTCAE V4.03 dated on june 14, 2010) : nausea, vomiting,diarrhea, neutropenia, anemia, leucopenia, fatigue, peripheral neuropathy, alopecia, loss of apetite. If others toxicities appear, they will be notified in the e-CRF. |
up to at least 6 months after Halaven® start
|
-Evaluation of percentage of patients in complete or partial response or in stability under Halaven® according to number of previous metastatic treatment lines
Time Frame: up to at least 6 months after Halaven® start
|
-Percentage of patients in complete or partial reponse or in stability under Halaven®.
This percentage will be calculated in patients treated by Halaven® in second, third or fourth line of treatment
|
up to at least 6 months after Halaven® start
|
-Evaluation of Progression Free Survival (PFS)
Time Frame: up to at least 6 months after Halaven® start
|
-Measure of time to progression (in months or in years) The PFS will be calculated from date of Halaven start to first progression date whatever the type of progression (local progression, progression of a previous metastasis and/or appearance of new metastasis, and/or new cancer).
|
up to at least 6 months after Halaven® start
|
Evaluation of overall survival
Time Frame: up to at least 6 months after Halaven® start
|
Measure of overall survival (in months or in years) Overall survival calculated from start of Halaven to death, whatever the cause, or date of last consultation if patients are alive at the 12/31/2017.
|
up to at least 6 months after Halaven® start
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-A03054-51
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Patients
-
Merrimack PharmaceuticalsSanofiCompletedER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer PatientsUnited States
-
Swiss Medical Food AGiOMEDICO AGCompletedCIPN in Adjuvant Colon Cancer Patients | CIPN in Adjuvant Breast Cancer PatientsGermany
-
Assiut UniversityRecruiting
-
Tata Memorial CentreActive, not recruitingBreast Cancer Patients
-
IRCCS SYNLAB SDNRecruiting
-
Radboud University Medical CenterCompleted
-
Damanhour UniversityAl-Azhar UniversityUnknownBreast Cancer PatientsEgypt
-
Damanhour UniversityAl-Azhar University; National Cancer Institute, EgyptUnknown
-
South Egypt Cancer InstituteUnknownBreast Cancer PatientsEgypt
-
Centre Jean PerrinCompletedLocal Breast Cancer PatientsFrance
Clinical Trials on Patients in long response during Halaven® treatment
-
Grupo Argentino de Tratamiento de la Leucemia AgudaNot yet recruitingChronic Lymphocytic Leukemia
-
Damascus UniversityCompletedDental Caries | Primary Teeth | PulpotomySyrian Arab Republic
-
Damascus UniversityActive, not recruitingAnesthesia, Local | Dental Anxiety | Behavior, ChildSyrian Arab Republic
-
Germans Trias i Pujol HospitalFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...Completed
-
Universitat Internacional de CatalunyaCompleted
-
University Health Network, TorontoCompleted
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity of BolognaNot yet recruitingInflammation | Hemodialysis Complication | Uremic; ToxemiaItaly
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKline; University of WashingtonCompletedProstate Cancer | Castration-resistant, MetastaticUnited States